ArticleScientific reports2016
Anion channelrhodopsins for inhibitory cardiac optogenetics.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 59 citations in OpenAlex.
- Optimal control of spiral waves in heterogeneous excitable media: non-monotonic efficacy of localized optogenetic inhibition.Journal of the Royal Society, Interface · 2026Article
- Theoretical analysis of low-power optogenetic suppression of action potentials in human ventricular cardiomyocytes expressed with potassium-selective channelrhodopsins.Scientific reports · 2026Article
- Computational Simulations Show Proof-of-Concept for Optogenetic Suppression of Ectopic Activity in Cardiac Stem Cell Therapy.Cardiovascular engineering and technology · 2025Article
- Monitoring and modulating cardiac bioelectricity: from Einthoven to end-user.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2024Review
- Optical mapping and optogenetics in cardiac electrophysiology research and therapy: a state-of-the-art review.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2024Review
- Human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) for modeling cardiac arrhythmias: strengths, challenges and potential solutions.Frontiers in physiology · 2024Review
- Opto-electronic feedback control of membrane potential for real-time control of action potentials.Cell reports methods · 2023Article
- Optogenetically mediated large volume suppression and synchronized excitation of human ventricular cardiomyocytes.Pflugers Archiv : European journal of physiology · 2023Article
- Cardiac optogenetics: shining light on signaling pathways.Pflugers Archiv : European journal of physiology · 2023Review
- Modulating cardiac physiology in engineered heart tissue with the bidirectional optogenetic tool BiPOLES.Pflugers Archiv : European journal of physiology · 2023Article
- Recent advances and current limitations of available technology to optically manipulate and observe cardiac electrophysiology.Pflugers Archiv : European journal of physiology · 2023Review
- Optogenetic Modulation of Arrhythmia Triggers: Proof-of-Concept from Computational Modeling.Cellular and molecular bioengineering · 2023Article
- Sequential absorption of two photons creates a bistable form of RubyACR responsible for its strong desensitization.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- The physiological response during optogenetic-based cardiac pacing in awake freely moving mice.Frontiers in physiology · 2023Article
- Advances and prospects of rhodopsin-based optogenetics in plant research.Plant physiology · 2021Review
- Optogenetic modulation of cardiac action potential properties may prevent arrhythmogenesis in short and long QT syndromes.JCI insight · 2021Article
- Cardiac optogenetics: a decade of enlightenment.Nature reviews. Cardiology · 2021Review
- The Effects of Repetitive Use and Pathological Remodeling on Channelrhodopsin Function in Cardiomyocytes.Frontiers in physiology · 2021Article
- Observing and Manipulating Cell-Specific Cardiac Function with Light.Advances in experimental medicine and biology · 2021Article
- Optogenetic Stimulation Using Anion Channelrhodopsin (GtACR1) Facilitates Termination of Reentrant Arrhythmias With Low Light Energy Requirements: A Computational Study.Frontiers in physiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Optical control of the heart muscle is a promising strategy for cardiology because it is more specific than traditional electrical stimulation, and allows a higher temporal resolution than pharmacological interventions. Anion channelrhodopsins (ACRs) from cryptophyte algae expressed in cultured neonatal rat ventricular cardiomyocytes produced inhibitory currents at less than one-thousandth of the light intensity required by previously available optogenetic tools, such as the proton pump archaerhodopsin-3 (Arch). Because of their greater photocurrents, ACRs permitted complete inhibition of cardiomyocyte electrical activity under conditions in which Arch was inefficient. Most importantly, ACR expression allowed precisely controlled shortening of the action potential duration by switching on the light during its repolarization phase, which was not possible with previously used optogenetic tools. Optical shortening of cardiac action potentials may benefit pathophysiology research and the development of optogenetic treatments for cardiac disorders such as the long QT syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.